These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17498767)

  • 1. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions.
    Bertaux C; Daelemans D; Meertens L; Cormier EG; Reinus JF; Peumans WJ; Van Damme EJ; Igarashi Y; Oki T; Schols D; Dragic T; Balzarini J
    Virology; 2007 Sep; 366(1):40-50. PubMed ID: 17498767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simian immunodeficiency virus is susceptible to inhibition by carbohydrate-binding agents in a manner similar to that of HIV: implications for further preclinical drug development.
    François KO; Auwerx J; Schols D; Balzarini J
    Mol Pharmacol; 2008 Aug; 74(2):330-7. PubMed ID: 18474667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4+ T lymphocytes.
    Pollicita M; Schols D; Aquaro S; Peumans WJ; Van Damme EJ; Perno CF; Balzarini J
    Virology; 2008 Jan; 370(2):382-91. PubMed ID: 17928023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes.
    Balzarini J; Van Herrewege Y; Vermeire K; Vanham G; Schols D
    Mol Pharmacol; 2007 Jan; 71(1):3-11. PubMed ID: 17056872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
    Balzarini J
    Antivir Chem Chemother; 2007; 18(1):1-11. PubMed ID: 17354647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection.
    Alen MM; Kaptein SJ; De Burghgraeve T; Balzarini J; Neyts J; Schols D
    Virology; 2009 Apr; 387(1):67-75. PubMed ID: 19264337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C Virus Resistance to Carbohydrate-Binding Agents.
    Izquierdo L; Oliveira C; Fournier C; Descamps V; Morel V; Dubuisson J; Brochot E; Francois C; Castelain S; Duverlie G; Helle F
    PLoS One; 2016; 11(2):e0149064. PubMed ID: 26871442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha.
    Toma S; Yamashiro T; Arakaki S; Shiroma J; Maeshiro T; Hibiya K; Sakamoto N; Kinjo F; Tateyama M; Fujita J
    J Viral Hepat; 2009 Jul; 16(7):506-12. PubMed ID: 19302339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyanion inhibitors of human immunodeficiency virus and other viruses. Part 2. Polymerized anionic surfactants derived from amino acids and dipeptides.
    Leydet A; El Hachemi H; Boyer B; Lamaty G; Roque JP; Schols D; Snoeck R; Andrei G; Ikeda S; Neyts J; Reymen D; Este J; Witvrouw M; De Clercq E
    J Med Chem; 1996 Apr; 39(8):1626-34. PubMed ID: 8648602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cell-based bicistronic lentiviral reporter system for identification of inhibitors of the hepatitis C virus internal ribosome entry site.
    Lourenço S; Boni S; Furling D; Cosset FL; Cahour A
    J Virol Methods; 2009 Jun; 158(1-2):152-9. PubMed ID: 19428584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection.
    Cheruvu S; Marks K; Talal AH
    Clin Liver Dis; 2007 Nov; 11(4):917-43, ix-x. PubMed ID: 17981235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convert hepatitis C virus into a non-enveloped virus like hepatitis A, by targeting its envelope rather than the RNA.
    Helmy A
    Med Hypotheses; 2006; 66(4):847-50. PubMed ID: 16229965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection.
    Hofmann WP; Soriano V; Zeuzem S
    Handb Exp Pharmacol; 2009; (189):321-46. PubMed ID: 19048206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad spectrum antiviral fractions from the lichen Ramalina farinacea (L.) Ach.
    Esimone CO; Grunwald T; Nworu CS; Kuate S; Proksch P; Uberla K
    Chemotherapy; 2009; 55(2):119-26. PubMed ID: 19155620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of HIV entry by carbohydrate-binding proteins.
    Balzarini J
    Antiviral Res; 2006 Sep; 71(2-3):237-47. PubMed ID: 16569440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of small-molecule compounds as inhibitors of HCV entry.
    Yang JP; Zhou D; Wong-Staal F
    Methods Mol Biol; 2009; 510():295-304. PubMed ID: 19009270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specificity of HIV inhibition by modified antisense oligonucleotides.
    Abramova T; Blinov V; Vlassov V; Gorn V; Zarytova V; Ivanova E; Konevets D; Plyasunova O; Pokrovsky A; Sandakhchiev L
    Nucleic Acids Symp Ser; 1991; (24):283. PubMed ID: 1841341
    [No Abstract]   [Full Text] [Related]  

  • 19. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
    Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
    Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyanion inhibitors of human immunodeficiency virus and other viruses. 5. Telomerized anionic surfactants derived from amino acids.
    Leydet A; Barragan V; Boyer B; Montéro JL; Roque JP; Witvrouw M; Este J; Snoeck R; Andrei G; De Clercq E
    J Med Chem; 1997 Jan; 40(3):342-9. PubMed ID: 9022800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.